NECLIFE — Nectar Lifesciences Balance Sheet
0.000.00%
- IN₹2.00bn
- IN₹85.94m
- IN₹20.11m
Annual balance sheet for Nectar Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 162 | 179 | 203 | 197 | 1,251 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6,107 | 4,450 | 4,822 | 4,715 | 1,165 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 13,548 | 12,312 | 12,838 | 12,376 | 2,530 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7,652 | 6,904 | 6,561 | 6,333 | 1,034 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 23,908 | 21,892 | 21,911 | 20,472 | 6,216 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10,038 | 8,909 | 9,728 | 10,215 | 261 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 13,029 | 11,246 | 11,218 | 10,911 | 393 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 10,879 | 10,646 | 10,692 | 9,561 | 5,823 |
| Total Liabilities & Shareholders' Equity | 23,908 | 21,892 | 21,911 | 20,472 | 6,216 |
| Total Common Shares Outstanding |